

# Introducing the new handheld, non-invasive Fast-Raster Scan Optoacoustic Mesoscopy (F-RSOM) device for therapy monitoring of cardiovascular diseases, diabetes and inflammatory skin conditions

## OUTCOMES

F-RSOM for market introduction



Novel ultrasound transducer for F-RSOM



Quality control mechanisms for good quality data



Portfolio of Therapy Monitoring Capabilities



4 peer reviewed publications



RSOM Explorer C50

## IMPACT

Tremendous potential benefits for patients with systemic diseases through earlier diagnosis and personalized treatment planning.



Strong growth within the European optoacoustic imaging market, with multiple lines of IP.



Continued strong European partnership between consortium members, from previous EU Horizon 2020 project INNODERM (Grant No. 687866).

## IMPRESSUM

For further information, please contact:



Prof. Dr. Vasilis Ntziachristos

Chair of Biological Imaging (CBI)

Technical University of Munich

Ismaninger Str. 22, 81675 Munich

Mail: [ibmi-projects@helmholtz-munich.de](mailto:ibmi-projects@helmholtz-munich.de)

Phone: +49 89 3187 3852



[winther.munichimaging.eu](http://winther.munichimaging.eu)

@winther2020



PHOTONICS<sup>21</sup>  
PHOTONICS PUBLIC PRIVATE  
PARTNERSHIP

*This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 871763.*



PHOTONICS<sup>21</sup>  
PHOTONICS PUBLIC PRIVATE  
PARTNERSHIP

# Fast optoacoustic mesoscopy, using the skin as a **WIN**dow for **THE**Rapeutic monitoring of local and systemic disease



[winther.munichimaging.eu](http://winther.munichimaging.eu)

@winther2020

Coordinator: Professor Vasilis Ntziachristos (TUM)

Start Date: January 2021 • End Date: December 2024



## ABOUT WINTHER

Our **VISION** was to develop the next-generation Fast-Raster Scan Optoacoustic Mesoscopy (F-RSOM) device with an encapsulated, handheld, lightweight design and capable of operating at faster speeds than its processor. The improved visualization capabilities of our low-cost device permits monitoring of progression and therapy of cardiovascular diseases, diabetes and inflammatory skin conditions.

The F-RSOM sends short light pulses to the skin, which in turn generates ultrasound waves in response to light absorption by skin molecules and structures, resulting in markedly superior contrast and specificity compared with other methods on the market. Tomographic analysis of the ultrasound waves reveals unprecedented volumetric views of the skin and disease manifestations. By using light pulses of different wavelengths, accurate spectroscopic information is obtained for morphological and biochemical features of skin, facilitating accurate and precise diagnoses, early detection, accurate and individualized treatment plans, and improved disease monitoring.

## OUR CONSORTIUM

Technical University of Munich – Germany

Sonaxis SA – France

Rayfos LTD – United Kingdom

iThera Medical GmbH – Germany

Humanitas University – Italy

## TECHNOLOGY BREAKTHROUGHS

High-resolution (7-30  $\mu\text{m}$ ), deep (3 mm), label-free imaging




High-contrast imaging of micro-vasculature



Quantification of tissue oxygenation and inflammation



Imaging of micro-vessel blood flow rate in response to stimuli (endothelial function)



*F-RSOM image of a melanoma (see He et al., 2022, Nature Communications)*

## CLINICAL NEED

Quantification of micro-vasculature metrics for **inflammatory skin diseases**



### Treatment

**monitoring** by topical and systemic drugs around skin wounds



Quantify **diabetes progression** from microvascular structure



Quantify **endothelial function** to monitor **CVD conditions** like atherosclerosis and heart failure.